Research programme: diagnostic and therapeutic drug discovery - Berg Pharma/Icahn School of Medicine at Mount Sinai

Drug Profile

Research programme: diagnostic and therapeutic drug discovery - Berg Pharma/Icahn School of Medicine at Mount Sinai

Latest Information Update: 16 Oct 2013

Price : $50

At a glance

  • Originator Berg Pharma; Icahn School of Medicine at Mount Sinai
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; CNS disorders; Endocrine disorders

Most Recent Events

  • 10 Oct 2013 Early research in Cancer, CNS disorders and endocrine disorders (diagnosis) in USA (unspecified route)
  • 10 Oct 2013 Early research in Cancer, CNS disorders and endocrine disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top